Insulin resistance is strongly associated with hypertension and is postulated to participate in the elevation of blood pressure, although the mechanisms involved are not understood. Recently, we reported that acute increases in plasma insulin levels in normal subjects resulted in increased serum levels of a sodium pump inhibitor, termed the digitalis-like factor (DLF), which has been implicated in both experimental and essential human hypertension. This study looked at the DLF response to hyperinsulinemia, achieved by an oral glucose tolerance test (OGTT), in the setting of a naturally occurring and self-resolving state of human insulin resistance, during third-trimester pregnancy. This model allowed us the further opportunity to compare the DLF response to insulin in the same subjects postpartum, after resolution of their insulin resistance. Administration of an OGTT during pregnancy and postpartum in the same subjects elicited a comparable serum glucose response but a significantly greater insulin response during third-trimester pregnancy, consistent with diminished insulin sensitivity (integrated insulin response during pregnancy: 1611 7 236 vs postpartum: 685 7 101 pmol/l, P ¼ 0.004). The time courses of the glucose and insulin responses were identical whether women were pregnant or not. Plasma free fatty acids fell significantly and to a comparable degree during pregnancy and postpartum, but the response was slower during pregnancy. DLF levels increased in response to oral glucose in both pregnant and nonpregnant states. The response was more rapid during pregnancy than after. These findings showed that the increment of insulin induced by oral glucose during pregnancy caused a more rapid rise in circulating DLF levels than it did during the nonpregnant state. At the same time, the response of circulating fatty acids to glucose is retarded during pregnancy. This suggests that the insulin resistance of pregnancy impairs insulin's influence on intermediary metabolism but not its influence on DLF. As a vasoactive substance, DLF might contribute to the hypertension characteristic of insulin-resistant states.
Introduction
Insulin exerts a variety of effects as a metabolic hormone, regulating whole body glucose utilization, as a growth factor and as a modulator of other hormones. Insulin resistance and hyperinsulinemia are associated with a number of pathological conditions, including diabetes and hypertension. 1, 2 However, the specific pathways and mediators of these abnormal changes are incompletely understood. Recently, we showed that infused insulin increases the circulating levels of a putative hormone, termed the digitalis-like factor (DLF). 3 This factor specifically inhibits the sodium pump in a manner analogous to known cardiac glycosides. 4, 5 Interest in DLF as a hypertensive agent arises from the demonstration of its ability to cause vascular smooth muscle (VSM) contraction in vitro, 6 the correlation of its concentration with blood pressure in human 7, 8 and experimental 9 hypertension, and the effect of DLF blockade by antibody to reduce blood pressure in hypertensive animals. 10 There have been several reports that serum DLF levels are elevated in diabetes. [11] [12] [13] [14] These findings suggest that DLF is one link between hyperinsulinemia and hypertension. 3 In our previous report, DLF was significantly increased in response to not only a hyperinsulinemic, euglycemic clamp but also in response to an oral glucose tolerance test (OGTT). 3 The present study was undertaken to better understand the relation between insulin and DLF in a naturally occurring and self-resolving state of insulin resistance and hyperinsulinemia, during normal human pregnancy. By the third-trimester of human pregnancy, women are significantly more insulin resistant, as manifest by hyperinsulinemia and by a variety of other assessments, than in the nonpregnant state. [15] [16] [17] We chose a dynamic measure of insulin resistance and a physiologic stimulus of insulin release, the OGTT, and studied the impact on DLF in women during the third trimester of pregnancy and in the same women at least 3 months postpartum.
Methods

Subjects
These protocols received approval of the Human Subjects Committee of the Brigham and Women's Hospital, and all subjects gave signed, informed consent prior to their participation in the studies. Women in their third trimester of pregnancy were recruited by posted notice in antenatal clinics associated with Brigham and Women's Hospital. These women were evaluated once by a clinical protocol during their third trimester and then reevaluated by the same protocol 3-6 months after their delivery. All women experienced normal pregnancies and were without other major intercurrent disease including diabetes, hypertension, liver, renal or cardiac disease. None were on medications except for antenatal vitamins during pregnancy.
Protocol
Because DLF may be influenced by sodium intake, women collected 24 h of urine for sodium measurement to ensure comparable sodium balance for each of the two studies. The urine collection was begun the morning prior to the study and ended with the first morning void of the study day. Women were studied fasting in the morning by means of a 3 h, 100 g OGTT. Glucose was administered as a 50% w/v glucose solution. Subjects were excluded if their diet, as determined by a nutritional survey, was low in carbohydrates or if they had difficulty in eating or if they had experienced nausea and vomiting in the days immediately prior to the study. During the OGTT, women lay in the left lateral decubitus position with a venous line placed for blood sampling. Blood was drawn fasting and at hourly intervals during the 3 h test for measurement of glucose, insulin, DLF and free fatty acids (FFAs).
Assays
Serum glucose was measured by means of a glucose analyser (Glucose Analyzer 2, Beckman Instruments Inc., Fullerton, CA, USA). A commercially available radioimmunoassay kit (Coat-A-Count Insulin, Diagnostic Products Corp., Los Angeles, CA, USA) was used to determine plasma insulin concentration. Specimens were assayed in duplicate using the manufacturer's method. FFAs were measured by the radioactive nickel method. 18 Urine sodium was measured by an ion-selective electrode (NOVA 1 Analyzer, NOVA Biomedical, Waltham, MA, USA). All assays had interassay coefficients of variation of less than 5%.
DLF was measured as inhibition of [Na,K]ATPase activity calculated as the percent reduction in the hydrolysis of g-labeled [
32 P]ATP according to a published method. 4 Ouabain (1.0 mmol/l) was used to define 100% inhibition of the enzyme. Each unit of inhibitory activity represented 1.0% of inhibition.
Statistics
Data are presented as the mean 7 s.e. Evaluation of changes over the course of the OGTT were evaluated by two-tailed ANOVA with repeated measures with post hoc, pairwise comparisons. Comparisons of single parameters at individual time points were carried out by Student's paired t-test for normally distributed data. Analysis of paired data was carried out by Pearson's product moment correlation analysis. A P-value of less than 0.05 was considered to be statistically significant.
Results
We studied seven women, administering OGTTs during their third trimester of pregnancy and again at least 3 months postpartum. The demographic profile of the subjects studied is given in Table 1 . Urine sodium content collected over 24 h was not different at the time of the third trimester and postpartum studies. Insulin resistance and DLF EW Seely et al
Insulin and glucose
Both fasting serum glucose levels and fasting plasma insulin levels were similar for the subjects when pregnant and when assayed 3 or more months after their pregnancy (fasting glucose: pregnant 4.12 7 0.23 vs nonpregnant 4.50 7 0.11 pmol/l, P ¼ 0.16; fasting insulin levels: pregnant 47.9 7 7.6 vs nonpregnant 49.3 7 7.6 pmol/l, P ¼ 0.89). In response to the 100 g oral glucose challenge, glucose levels increased significantly, with the maximum concentration occurring at 1 h both during pregnancy and after delivery (Figure 1, serum While the glucose values were somewhat higher at each time point during the OGTT for the women when pregnant, there were no significant differences at any time point between the two OGTT studies. The integrated glucose response, estimated as area under the curve (AUC), was not significantly different between the two studies.
In response to the oral glucose load, all subjects demonstrated significant increases in insulin levels during pregnancy and postpartum (see Figure 2 , plasma insulin values when pregnant: 1 h, 764 7 152; 2 h, 554 7 94; 3 h, 528 7 88 pmol/l; P ¼ 0.0003; plasma insulin values when nonpregnant: 1 h, 367 7 88; 2 h, 214 7 28; 3 h, 158 7 26 pmol/l; P ¼ 0.001). The insulin response was significantly greater at each time point during the OGTT in pregnant women compared to corresponding time points in the same women measured when nonpregnant. The integrated insulin response to OGTT estimated as the AUC was also significantly greater during pregnancy than in the nonpregnant state (AUC: pregnant 1611 7 236 vs nonpregnant 685 7 101 pmol/l, P ¼ 0.004).
Serum FFAs
The mean fasting serum FFA concentration was somewhat higher during pregnancy than in the nonpregnant state, but this difference was not statistically significant. Serum FFA concentrations fell in response to the OGTT during pregnancy and in the nonpregnant state (pregnant: baseline, 21.9 7 2.5; nadir, 4.8 7 0.3 mmol/l; P ¼ 0.0003; nonpregnant: baseline, 21.2 7 1.8; nadir, 4.3 7 0.3 mmol/l; P ¼ 0.0002).
The rate of fall of FFA levels was more rapid in the women when they were studied postpartum than during pregnancy. The magnitude of the fall in the first hour of the OGTT as a function of the original FFA concentration was substantially greater in the postpartum as compared with the pregnant state (DFFA 0-1 h/initial FFA concentration: pregnant 0.56 7 0.04 vs nonpregnant 0.70 7 0.04, P ¼ 0.00003). Six of seven reached their lowest FFA level at 2 h when studied after pregnancy while six of seven reached their lowest FFA levels at 3 h during pregnancy. As shown in Figure 3 , the FFA levels postpartum were also significantly lower at 1 and 2 h postpartum than during pregnancy (1 h pregnant FFA 9.4 7 1.1 vs 1 h postpartum FFA 6.1 7 0.5 mmol/l, P ¼ 0.04; 2 h pregnant FFA 5.5 7 0.3 vs 2 h post-partum FFA 4.5 7 0.4 mmol/l, P ¼ 0.02). Some have estimated insulin sensitivity as the product of plasma insulin concentration Figure 1 Serum glucose concentration during two standard 100 g OGTTs, one administered during the third trimester of normal pregnancy (K) and the other at least 3 months postpartum (*) in the same subject. The glucose levels rose significantly above the fasting baseline value (ANOVA third-trimester P ¼ 0.0001, postpartum P ¼ 0.001). Figure 2 Plasma insulin concentration during two standard OGTTs, one administered during the third trimester of normal pregnancy (K) and the other at least 3 months postpartum (*). Insulin levels rose significantly above baseline levels for both studies (ANOVA third trimester P ¼ 0.0003, postpartum P ¼ 0.001). As shown by an asterisk, the insulin concentrations were significantly greater at 1, 2 and 3 h after glucose administration in the third trimester as compared to the postpartum values. The AUC of the insulin response was significantly greater during pregnancy than postpartum, P ¼ 0.0004. multiplied by the concomitant value of a particular insulin-sensitive response, most often glucose, divided by a constant 22.5, as a way to describe quantitatively the insulin resistance. When such an approach was applied to FFA, a pattern somewhat different from Figure 3 emerges: thirdtrimester insulin Â FFA/22.5 baseline: 200+52, 1 h, 1365+374; 2 h; 654+90; 3 hr, 457+83; P ¼ 0.001 compared with postpartum baseline: 182+28, 1 h; 378+76; 2 h, 169+22; 3 h; 169+30, P ¼ 0.006. The 1, 2 and 3 h values were each significantly greater third trimester than postpartum (paired t-test, Po0.05). This estimation suggests that insulin was only about one-third as effective during pregnancy in modifying FFA levels as postpartum. Another apparent difference was that the response postpartum had normalized by 2 h, whereas during pregnancy the response was still elevated at 3 h.
DLF response
Fasting serum DLF levels pregnant and postpartum were comparable (fasting DLF: pregnant 3.2 7 0. 7 vs nonpregnant 2.8 7 1.3 U, P ¼ 0.71). During pregnancy, the serum DLF level increased progressively in response to the OGTT. The mean peak value was significantly greater than the baseline value (baseline 3.2 7 0.7 vs peak 6.4 7 0.9 U, P ¼ 0.01). In the same women restudied postpartum, the serum DLF level increased from baseline to peak, but this change was not statistically significant (baseline 2.8 7 1.3 vs peak: 5.0 7 1.6 U, P ¼ 0.18). During pregnancy, five of seven subjects achieved their peak DLF concentrations at 2 h after administration of glucose. All but one of the subjects when studied postpartum achieved the maximal DLF response at 3 h, P ¼ 0. 19 . Subjects when pregnant demonstrated a significantly greater DLF response at 1 and 2 h than their corresponding responses when not pregnant (1 h: pregnant 4.6 7 0.7 vs nonpregnant: 2.1 7 0.5 U, P ¼ 0.05; 2 h, pregnant: 6.1 7 1.0 vs nonpregnant 3.5 7 0.5 U, P ¼ 0.03, Figure 4) . The AUC for the integrated DLF response to the OGTT during pregnancy was higher than that achieved in the nonpregnant state (pregnant: 14.8 7 2.2; nonpregnant: 9.4 7 0.7 U of area, P ¼ 0.056).
The rise in insulin levels in response to the OGTT during pregnancy was earlier than the DLF response, anticipating the DLF response by B1 h. This was reflected in a nonsignificant correlation between DLF and insulin over the OGTT conducted during pregnancy (R ¼ 0.35, P ¼ 0.07). However, if the DLF response was offset by an hour, the two responses were then significantly correlated during pregnancy (R ¼ 0.58, P ¼ 0.006). The DLF response to the OGTT in the postpartum period reached a maximum B2.0 h after insulin achieved its peak. Consequently, comparison of the DLF response to the concomitant insulin level was not significantly correlated (R ¼ 0.10, P ¼ 0.59). However, if the DLF response was offset by 2 h, the responses paralleled each other much more closely (R ¼ 0.51, P ¼ 0.06).
Discussion
Our previous study demonstrated an increase in serum DLF activity in response to increased serum insulin levels achieved either by means of a euglycemic, hyperinsulinemic clamp or by OGTT Figure 3 Plasma FFA concentration during two standard OGTTs, one administered during the third trimester of normal pregnancy (K) and the other at least 3 months postpartum (*). Both studies brought about significant decreases in FFA levels as compared to baseline (ANOVA third trimester P ¼ 2.8 Â 10
À8 , postpartum P ¼ 7.8 Â 10 À9 ). As shown by an asterisk, the values at 1 and 2 h were significantly greater during pregnancy. Figure 4 Serum DLF levels (measured as inhibition of [Na,K] ATPase) during two standard OGTTs, one administered during the third trimester of normal pregnancy (K) and the other at least 3 months postpartum (*). DLF levels increased significantly baseline to peak during pregnancy and from 1 h values to peak postpartum. Additionally, DLF levels were significantly higher at 1 and 2 h during the third trimester as compared with the postpartum study as indicated by an asterisk. The AUC of the DLF response was greater during pregnancy than postpartum, P ¼ 0.056.
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EW Seely et al in normal subjects. 3 Because many states that manifest hyperinsulinemia also demonstrate insulin resistance, we were interested in the response of DLF to hyperinsulinemia in the setting of insulin resistance. To study this, the DLF response to increased insulin was assessed by OGTT during and after pregnancy.
The subjects studied all had uncomplicated pregnancies. Fasting insulin levels during pregnancy were comparable to those measured in the nonpregnant state, as reported. 17 However, hyperinsulinemia was clearly demonstrated in response to the OGTT during and after pregnancy. While both OGTTs produced similar increases in serum glucose levels, significantly greater insulin levels were achieved during pregnancy, reflecting the insulin resistance of pregnancy. [15] [16] [17] There have been studies to suggest that glucose and FFAs respond differentially to hyperinsulinemia in the setting of insulin resistance. 19 In our study, fasting FFA levels were not different in the pregnant and nonpregnant states, and FFAs fell to comparable levels during the OGTT, but the rate of fall was slower during pregnancy, further suggesting insulin resistance. Furthermore, using a model of estimating insulin resistance, there is the suggestion that insulin resistance is manifest longer than the FFA data alone might suggest.
Baseline DLF values were similar during pregnancy and postpartum as were the maximum levels achieved during the two OGTT studies. The OGTT, whether administered during pregnancy or during the nonpregnant state, caused a progressive increase in DLF activity. The distinguishing feature was that the DLF responded to the rise in insulin more rapidly during pregnancy. Clearly, DLF responds to insulin during pregnancy when women were hyperinsulinemic and presumably insulin resistant. It is possible that the relatively faster DLF response in the pregnant state reflects the higher insulin levels.
Why do not all third-trimester women manifest elevated blood pressures at the same time insulin resistance occurs if DLF links the two? Existing animal experiments demonstrate that DLF and other sodium pump inhibitors produce vascular smooth muscle contraction only after adequate levels of inhibitor are present for a few hours. 20 Consequently, if fasting DLF levels are not increased in normal pregnancy, and if DLF elevations were limited to the immediate postprandial period, then it is unlikely that DLF would exert much of an effect on blood pressure. However, in pre-eclampsia, insulin resistance is much more pronounced, 21 and there is evidence that even baseline insulin levels are increased in pre-eclampsia 22, 23 and the time to normalize blood glucose levels is lengthened. 23 Consequently, there appears to be a greater and more prolonged stimulus for DLF production in preeclampsia than even in normal pregnancy, which may explain the chronically sustained increases in DLF that have been found in pre-eclampsia and may explain why DLF would exert a hypertensiogenic effect in that setting. [24] [25] [26] While the evidence for DLF mediation of the hypertension of pre-eclampsia is limited, it is of interest to note that women with preeclampsia treated with a digoxin Fab fragment (which binds and inactivates the DLF) showed marked reductions in blood pressure. 27, 28 It is possible that the increase of DLF levels in response to the OGTT was not a direct consequence of insulin but was caused by a secondary factor. While these experiments do not implicate any such factor, the difference in timing between FFA and DLF responses makes FFA unlikely mediators of the DLF response. FFA also have sodium pump inhibitory activity, and some have suggested that they represent the endogenous DLF. 29 However, the observed decline in their concentration with the concomitant increase in DLF levels argues that their contribution to DLF activity would at best be small.
In summary, increased DLF in response to increased insulin was more rapid during a state of insulin resistance, the third trimester of pregnancy, than after pregnancy. States of increased insulin resistance and hypertension occur in pregnancy [21] [22] [23] 30 and among essential hypertensives, for example, Syndrome X.
1,2 Our results present the possibility that DLF explains part or all of the increase in blood pressure that often accompanies hyperinsulinemic states.
